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Abstract
Background: Wolfsburg HPV Epidemiological Study (WOLVES) is a population-based cohort study on HPV
infections and associated diseases in the pre-vaccination era in young women in Wolfsburg, Germany.
Methods: Women born 1983/84 or 1988/89 were invited to participate. Participants were recruited in gynecology
practices, and completed a questionnaire with socioeconomic, sexual and medical data including vaccination
status. Pelvic examination with Pap smear and HPV testing (HC2 = Hybrid Capture 2) was obligatory. HC2-positive
and 10% of HC2-negative samples were tested for specific HPV types with SPF-10-PCR, and in inconclusive cases
with DNA sequencing. Women with genital warts (GW) and those with atypical Pap smears were transferred for
colposcopy. GWs were classified as typical condylomata acuminata (TCA), flat condyloma (FC) and seborrheic
wart-like (SWL).
Results: In total, 1258 subjects were recruited from the target population of 2850 (44.1%). Overall the prevalence of
HC2 low-risk (LR) types was 8.5%. HPV6 was the most frequent LR type (2.1%), followed by HPV42 (1.1%), HPV11 and
HPV44 (each 0.4%). LiPA showed a low sensitivity for HPV types 42, 90 and 91, which were detected only by HC2
and HPV sequencing. Nine women (0.7%) were transferred with incident GW: five TCA, two FC and two SWL. All
TCA were associated with HPV6 in corresponding cervical swabs and warts. Tissues of SWL contained HPV6 (n = 1)
and HPV16 (n = 1). The cumulative life-risk for GW was 1.4% in the 1988/89 and 4.8% in the 1983/84 cohort. Eight of
107 HC2-LR + and five of nine cases of GW had concomitant abnormal Pap smears. All CIN lesions could be linked
to high-risk HPV types but borderline and low-grade abnormal smears were explained by vaginal and cervical TCA
in four cases.
Conclusions: HC2 was a specific test for the detection of established and potential LR types. In this first WOLVES
analysis, HPV6 was the most frequent HPV type and the single LR type linked to disease. The observed GW
incidence of 715 per 100,000 fits well with estimates of healthcare providers. Although life risks for GW were lower
than in Scandinavian analyses, the societal burden within the WOLVES populations was considerable.
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Background
Most clinical data on the frequency of genital warts (GW)
are published from clinics specialized in sexually transmit-
ted infections (STI) or other health institutions with a
focus on the treatment of diseases of the lower genital
tract, while studies estimating the impact of GW on health
budgets are based on data from healthcare providers [1,2].
Neither approach is optimal to measure the true preva-
lence and incidence of GW in the general population, nor
to estimate the role of human papillomavirus (HPV) low-
risk (LR) types. The frequency of GW in STI clinics de-
pends on transfer policies and awareness among patients
and transferring institutions, while the analyses of health-
care providers rely on ICD-10 codes, which may follow
more economic than clinical aspects. To date, real-life
population-based data on the epidemiology of LR-HPV
and GW are not available for Germany. Furthermore, the
term, “genital wart” is not well defined and in addition to
condylomata acuminata may include mollusca contagiosa,
verruca vulgaris, dermatofibroma and other skin tumors.
There is also an ongoing controversy about the best
approach to measure the burden of HPV infections in
the general population. In epidemiological and screening
studies, Hybrid Capture 2 (HC2) showed a lower analy-
tical sensitivity for high-risk HPV (HR-HPV) compared
with different PCR-based methods. However, the clinical
sensitivity of HC2 for HR-HPV-associated lesions like
cervical intraepithelial neoplasia grade 3 (CIN3) and cer-
vical cancer ranged from 93% to 100% in several con-
trolled and randomized controlled trials. Therefore, HC2
is considered to be the best validated HPV test for
cervical cancer screening [3-5]. Furthermore, HC2 is a
robust test that showed almost no intralaboratory and
interlaboratory variation in quality assessment trials [6].
As HC2 defines a clinically relevant HR-HPV infection
it also seems useful for epidemiological studies to distin-
guish probably irrelevant latent from clinically meaning-
ful HPV infections. Although this concept has been
confirmed with a high level of evidence (LOE) for the
detection of HR-HPV types with HC2, the clinical im-
portance of detection of HC2-LR-HPV types has not yet
been validated with a comparable LOE.
We have used data from a population-based cohort
study in Wolfsburg, Germany and HC2 testing to deter-
mine the prevalence of HPV infection and associated
disease. Here we report the first results on the preva-
lence of LR-HPV types and associated diseases. Detailed
analysis of HR-HPV types will be published separately.
Methods
Study population
The Wolfsburg HPV Epidemiological Study (WOLVES)
is a population-based cohort study on the prevalence
and incidence of HPV infections and associated diseases
in women of two predefined birth cohorts (born in 1984/4
or 1988/9) recruited between 19 October 2009 and 31 De-
cember 2010. The study was designed to measure the role
of HPV infection in the pre-vaccination era and changes
over a 5-year observation period. The residents’ registra-
tion office provided a list of all women born either 1983/
84 or 1988/89 with a first residency in Wolfsburg city and
2850 women were invited by letter to attend cervical can-
cer screening. The invitation included information on the
intention of the study and the voluntary participation. To
be recruited, women had to attend one of 18 gynecologists
in private practices in the city of Wolfsburg for routine
Pap smear screening. Participants had to give written con-
sent and complete a short standardized questionnaire in
the private practice. Then they underwent a pelvic exami-
nation with visualization of the uterine cervix. Pap smears
were taken using spatula and endocervical brush. A se-
cond sample was then obtained with a Qiagen Cervical
Sampler (Medscan, Uppsala, Sweden), and suspended in
1 ml of specimen transport medium (STM/Qiagen Inc.,
Hilden, Germany) for HPV DNA testing.
The questionnaire included questions on education,
birth country, marital status, pregnancies, parity, contra-
ception, smoking, number of sexual partners, age at sex-
ual debut, history of abnormal Pap smears, STI and
GW. Furthermore, the referring gynecologist collected
information on HPV vaccination status by checking the
certificate of vaccination.
Patients were transferred for colposcopy if they suffered
from GW and/or had abnormal Pap smears conspicuous
of high-grade lesions or had Pap smears classified as
borderline/low-grade and tested positive for high-risk
(HR)-HPV.
Colposcopists classified the type of transformation
zones according to the Barcelona nomenclature of the
International Federation for Cervical Pathology and Col-
poscopy (IFCPC) [7]. In cases of type 1 or type 2 trans-
formation zone with visible squamous columnar junction
(SCJ), colposcopy was regarded as satisfactory. Any vi-
sible lesion underwent histological assessments with
punch biopsies. No random punch biopsies were taken
if colposcopy findings were normal. In cases of type 3
transformation zones, colposcopy with not fully visible
SCJ was regarded as unsatisfactory and endocervical
curettage (ECC) was obligatory. Type 3 transformation
zones with visible lesions underwent punch biopsies and
ECC.
A variety of skin and mucosal lesions may be classified
as GW. Lesions were included in the category “genital
warts” only if they were classified on colposcopy as:
1. “typical condylomata acuminata” (TCA) for lesions
that showed the typical acuminate morphology
(Figure 1A)
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2. “flat condylomata” (FC) for genital papillomas with a
more hyperkeratotic and papillomatous surface and
flat condylomata with a smooth surface and non-
pigmented papules (Figure 1B)
3. “seborrheic wart-like lesions” (SWL) of the dry skin
of the external anogenital area if intraepithelial
neoplasia was excluded on histology (Figure 1C).
Naevi, vulvar intraepithelial neoplasia (VIN), hirsutoid-
papillomas and molluscacontagiosa were excluded.
Colposcopists and pathologists were blinded to HPV
genotyping results at the time of classification of GW.
All primary HPV testing was undertaken using the HC2
assay (HC2/Qiagen Inc., Hilden Germany). All samples
were analyzed for the presence of at least 13 HR-HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68)
following the manufacturer’s instructions. Therefore, a
positive HR-HPV result in this study refers to a patient
positive for one or more of the 13 HR-HPV types included
in the probe mix. Infection with LR-HPV types was also
investigated by HC2. The LR probe mix included HPV
types 6, 11, 42, 43 and 44. Samples were considered po-
sitive if they attained or exceeded the FDA-approved
threshold of 1.0 pg HPV DNA/ml, which corresponds to
1.0 relative light unit (RLU).
All samples that tested positive for LR-HPV and/or
HR-HPV with HC2 and 10% (every tenth) of all HC2-
negative samples underwent HPV genotyping. HPV
genotyping was performed as described previously using
SPF-10-PCR, followed by Reverse Line Probe Assay
LiPA Extra (SPF-10-PCR) [8]. Briefly, total DNA was iso-
lated from the cervical samples with the use of a Mag-
NAPure device (Roche, Indianapolis, IN) and analyzed
with the use of the INNO-LiPA Extra HPV prototype
assay (Innogenetics, Inc, Gent, Belgium) according to
the manufacturer’s instructions. According to good la-
boratory practice guidelines, all PCR manipulations were
performed in a laboratory that was separate from the
other laboratory rooms. All PCR reactions were under-
taken with 10 μl input DNA in a final volume of 50 μl
using provided reagents from Innogenetics, 10 min 37°C,
9 min 94°C, and 40 cycles of 30 sec of denaturation at
94°C, followed by 45 sec of 52°C annealing temperature
and 45 sec of extension at 72°C run on a MJ Thermocy-
cler PCT 200. The PCR product was then denatured and
a 10 μl aliquot hybridized to one strip at 49°C for 60 min,
followed by multiple washing steps. The INNO-LiPA
Extra test allowed identification of 13 established high-risk
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68), five known or putative high-risk types (26, 53, 66, 73
and 82) [9,10], seven LR-HPV types (6, 11, 40, 43, 44, 54
and 70), additional non-differentiated HPV types, and
types with undefined risk (74 and 69/71) [11,12]. The
strips were analyzed on a flatbed scanner with the use of
LiRAS prototype software (Innogenetics, Inc), which dis-
plays the patterns and relative intensity of positive bands
as arbitrary grey-tone values between 0.1 and 1.0 and
allows direct data transfer to Excel spreadsheets. All HC2-
LR positive samples, which were negative in the LiPA
Extra, were retested with the CP4/5 PCR. The positive
PCR products were purified with the Qiagen Gel Extrac-
tion Test QIAquick and then directly sequenced with the
CP4 primer [13]. Sequencing allowed the identification of
HPV subtypes that were not detectable by LiPA Extra.
Figure 1 A: Typical condyloma acuminatum; B: Flat condyloma;
C: Seborrheic wart like lesion.
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Any lesion suspicious of high-grade neoplasia had to
undergo histological assessment and patients with GW
were tested for histological confirmation of the diagnosis
with biopsies. Paraffin embedded tissue blocks of GW
and/or cervical intraepithelial neoplasia (CIN), vulvar in-
traepithelial neoplasia (VIN), and vaginal intraepithelial
neoplasia (VAIN) underwent HPV-genotyping with SPF-
10 and LiPA. Data for the prevalence of HR-HPV, co-
factors associated with the risk of HR-HPV infection,
and the association between specific HR-HPV subtypes
and abnormal Pap smear test results will be published
separately.
The study was designed to provide a one-time cross
sectional study of the 1983/84 cohort, whereas the 1988/
89 cohort will be followed by annual examination for
5 years. In the year 2014/15, women born 1993/94 will
be invited for a one-time examination. Overall WOLVES
will allow investigation of individual changes in HPV in-
fection during follow-up and a comparison of prevalence
of HPV infections in different age cohorts over time.
WOLVES was approved by the ethics committee of
the physicians’ association of Lower Saxony in Hannover,
Germany (Bo/07/2009).
Statistical analysis
All statistical analyses were undertaken by an independ-
ent statistician who did not participate in the collection
of data.
The association between HPV infection and explanatory
variables was analyzed in univariate (Mann–Whitney-U
Test) and multivariate (logistic regression) analyses. Statis-
tical analyses were performed with the validated program
Testimate Version 6.5 from IDV Gauting (validation of
software, hardware and user according to FDA 21 CFR
Part 11). Logistic regression was calculated using SAS.
Results
Between 19 October 2009 and 31 December 2010, 659
(43.8%) of 1504 registered women born 1983/84 and 599
(44.5%) of 1346 women born 1988/89 were recruited.
The socioeconomic status of the recruited population
reflected the general population in Wolfsburg.
LR-HPV prevalence
In the 1983/84 cohort, 52/659 (7.9%) cervical samples
tested positive for LR-HPV types with HC2, while in the
1988/89 cohort the corresponding prevalence was 55/
599 (9.2%) (see Table 1). Within the 1983/4 cohort, 34/
52 cases tested positive for HR- and LR-HPV types,
while the remaining 18 patients tested positive for LR
types only. The corresponding findings for the 1988/89
cohort were 32/55 and 23 cases, respectively.
Co-factors of LR-HPV infection
Univariate analyses with Mann–Whitney-U Test and mul-
tivariate analysis using logistic regression produced iden-
tical results. Univariate analyses showed no association
between risk for HC2-LR and smoking, education, contra-
ception, country of origin, age at first menstruation and
history of STI. A higher number of sexual partners was
associated with a significantly increased risk for detection
of HC2-LR types in both age cohorts, but this effect was
more pronounced in the 1983/84 cohort. Young age at
first intercourse was found to be a weak risk factor for
HC2-LR, but only in the 1983/84 cohort (Figure 2). Multi-
variate analysis identified only the number of sexual part-
ners as significant risk factor for HC2 (Table 2). However,
as this is not a confirmative study, these results should be
interpreted only descriptively.
Restricting the analyses to women positive only for
LR-HPV types showed no difference in risk factors bet-
ween LR-HPV only and LR-/HR-HPV (data not shown).
HPV genotyping
Two of 107 HC2-LR positive samples failed in HPV
genotyping with SPF-10-PCR. LR-HPV genotypes 6, 11,
40, 42, 43, 44, 54, 61, 70, 72 and 81, as defined by
Munoz [10], were detected in 38 cases. HPV types 69,
71 and 74, which are closely related to LR types and are
not associated with cancer [11], were detected in an-
other five cases. HPV types 53 and 66, which are listed
as putative HR types by IARC [12], were detected in ano-
ther 13 cases. The genotype remained unknown in ano-
ther six PCR-positive cases.
Based on SPF-10-PCR genotyping of HC2-LR positive
cases, HPV6 was the most frequent LR type (n = 26), fol-
lowed by HPV11 (n = 5), HPV44 (n = 5), HPV43 (n = 2),
HPV54 (n = 1) and HPV70 (n = 1).
In 43/105 samples, genotyping showed either no HPV
types at all or only HR types (Figures 3 and 4). In 29
HC2-LR-positive samples, genotyping detected only HR-
HPV types; LiPA detected only HR-HPV in 26 cases that
tested positive for LR-HPV (± HR types) with HC2. PCR
and LiPA showed negative results in another 14 cases.
Unknown HPV types and negative PCR results were ob-
served exclusively in HC2-LR-positive cases that tested
negative for HC2-HR.
Cases with negative PCR, but positive HC2-LR, did
not differ in HC2-LR signal strength from other HC2-LR
positive samples. The mean signal strength was 155.43
Table 1 Age-dependent prevalence of LR-HPV (HC2) in
cervical samples
LR-HPV positive N LR-HPV positive% 95% CI
1983/84 52/659 7.9 5.95 – 10.22
1988/89 55/599 9.2 6.99 – 11.78
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RLU with a range from 1.05 to 1,021.33 RLU. All 14
cases with HC2-LR-positive but SPF-10-PCR-negative
results and all six HC2-LR-positive cases with unknown
genotypes underwent further evaluation by CP4/5 PCR
and direct DNA sequencing of the amplification pro-
duct. Among these 20 cases, one sample failed, HPV42
was detected in 13 samples, HPV91 in three cases, while
HPV90, HPV43 and HPV45 were each found in one of
the remaining cases.
Eighty-nine samples that tested negative for LR and
HR types with HC2 were randomly selected for genoty-
ping. LiPA detected two cases of LR-HPV infection as
defined by IARC (one HPV44 and one HPV54) and two
cases associated with HPV74.
Genital warts
Thirty women had a history of GW, 26/659 (3.9%) in the
1983/84 cohort and 4/599 (0.7%) in the 1988/89 cohort.
Among cases with GW prior to the start of WOLVES,
22 underwent pharmaceutical treatment and eight were
treated surgically. Another five women born 1983/84
and four born 1988/89 were transferred to colposcopy
because of first-time GW.
The colposcopy classification was TCA in five cases,
FC in two cases and SWL in two cases. Both cases of
SWL and one FC tested negative for HC2-LR, while all
five cases of TCA and one FC were associated with
Figure 2 Risk factors for LR-HPV infection. A: 1983/84 cohort; B: 1988/89 cohort.
Table 2 Multivariate analysis using logistic regression
Odds ratio 95% CI Odds ratio 95% CI
2–5 vs 1 partner >5 vs 1 partner
1983/84 9.8 3.1 – 28.0 21.5 7.1 – 61.4
1988/89 2.9 1.6 – 5.4 6.2 3.0 – 12.8
Number of lifetime sexual partners was the single significant risk factor for
HPV infection.
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cervical HC2 samples that tested positive for LR-HPV.
Genotyping detected HPV6 in all five cervical samples
of patients with TCA either as single HPV or as one of
multiple HPV types. In two TCA cases, biopsies were
taken and PCR genotyping confirmed HPV6 in the tis-
sues. The remaining patients with TCA and FC refused
biopsies. Both SWL underwent histological assessment.
One case of warts close to the pubic mount was asso-
ciated with HPV6, while the second case of SWL of the
greater lips of pudendum contained HPV16.
All patients with TCA and SWL were smokers and not
HPV vaccinated. One patient with FC of the perineum
was a smoker and received a full course of quadrivalent
HPV vaccination 3 years prior to diagnosis. The cervical
sample tested negative for HC2-LR types. The remaining
patient with FC never smoked and was not vaccinated.
The cervical sample tested positive for HR- and LR-HPV
types. Genotyping showed HPV types 51, 52 and 66.
Abnormal smears and colposcopy findings
Overall 8/107 LR-HPV-positive women showed abnor-
mal Pap smears, including five cases of low-grade squa-
mous intraepithelial lesion (LSIL) and three cases with
borderline cytology. All occurred exclusively in wo-
men who tested positive for HC2 LR and HR, while no
case was observed in HC2-LR-positive/HC2-HR-negative
participants.
Five of nine patients with GW had abnormal Pap
smears classified as borderline (n = 1), low-grade squa-
mous intraepithelial lesion (n = 3) and high-grade squa-
mous intraepithelial lesion in one patient with SWL
whose cervical sample tested positive for HR-HPV, but
negative for LR-HPV types.
The colposcopic evaluation of all five TCA cases
excluded any cervical abnormality in three women with
normal or borderline Pap smears. The remaining two
cases had Pap smears classified as LSIL. One case of
Figure 3 Genotyping results with LiPA for all 41 cases that tested positive for LR-HPV only with HC2 and HPV-DNA sequencing of
LiPA-negative/HC2-LR-positive cases.
Figure 4 Genotyping results with LiPA of all 66 cases that tested positive for LR- and HR-HPV with HC 2. HR-types included: HPV types
16, 18, 31, 33, 35, 38, 45, 51, 52, 56, 58, 59 and 68.
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TCA was diagnosed with a CIN1 lesion. PCR genotyping
of the CIN1 tissue detected HPV51 as single HPV type.
The remaining TCA cases had cervical condylomata acu-
minata, the tissue contained HPV6 as single HPV type.
Discussion
WOLVES has provided the first real-life data on the
epidemiology of LR-HPV and associated diseases in
Germany. Of particular interest is the observation that
the prevalence of LR-HPV is declining in the 1983/84
cohort, suggesting that spontaneous regression is com-
mon. Furthermore, the results from this analysis also
suggest that the number of sexual partners is the most
important risk factor for LR-HPV infection. The re-
ported HC2-LR prevalence of 7.9–9.2% is concordant
with the 8.5% prevalence in 25–34 year-old Italian
women observed by Rossi and coworkers [14]. The Italian
trial found HPV types 6 and 11 in only 19.9% of all HC2-
LR-positive samples compared with 27.6% (29/105) in the
WOLVES population. However, genotyping could not de-
tect any HPV type in 14 HC2-LR-positive samples and
found only HR types as defined by IARC in another 29
samples, 26 of which tested positive for HC2-HR and -LR.
Using additional data from CP4/5 PCR and direct HPV-
DNA sequencing, 18 of 20 HC2-LR-positive cases with ei-
ther PCR-negative results or unknown HPV genotypes
were classified as HPV infections with types 42, 43, 45, 90
and 91. HPV-genotyping using SPF-10-PCR is known to
have a very high analytical sensitivity for most HPV types
but obviously this system has a lower sensitivity to de-
tect HPV42, as described previously [8], although this
HPV type was the second most common LR-type in the
WOLVES study population. Because of this weakness, the
observed overall sensitivity of SPF-10-PCR for LR-HPV
was lower than for HC2. Based on SPF-10-PCR genoty-
ping, HPV6 was the most frequently found LR-HPV type.
HPV42 and, to a lesser extent, HPV90 and HPV91 in-
fections probably account for most cases classified as
HC2-LR- and HC2-HR-positive, SPF-10-PCR–LR-nega-
tive; therefore, we conclude that the majority of HC2-LR-
positive results are explained by infections with LR-types,
as defined by Munoz et al., while the remaining HC2-LR-
positive cases can be attributed almost entirely to infec-
tions with other probable LR types (HPV types 74, 90 and
91) and HPV types with undetermined risk (HPV types 53
and 66). We found almost no signs of HC2-LR cross-
hybridization with HR-types. The detection of HR-HPV
types with SPF-10-PCR in HC2-HR-negative women and
identification of LR-HPV by SPF-10-PCR in few HC2-
negative controls is most likely explained by latent or low
replication infections. The finding that HC2-LR identifies
HPV types 6, 11, 42, 43 and 44 that are included in the
probe mix and all related HPV types with LR properties
is probably attributable to the use of an RNA probe
hybridizing to the full genome. The single “low-risk type”,
according to Munoz et al., that was missed by HC2-LR
was HPV70; in the WOLVES study, all six cases tested
positive for HC2-HR. However, it has been shown that
HPV70 immortalizes primary keratinocytes [15]. A pro-
posal for a new classification of HPVs by Bernard et al.
concluded that HPV70 is a HR type of species 7, closely
related to HPV18 and HPV74, a LR type of species 10
closely related to HPV types 6, 11 and 44 [16]. Both pro-
posals are in agreement with our findings.
HPV6 was the most frequent of all identified LR-HPV
types (26 cases) and, to date, the single LR type asso-
ciated with clinical disease in our study population. One
focus of WOLVES is a careful colposcopic distinction
between HPV-related lesions in groups with different spe-
cific morphologies. We hypothesize that TCA are linked
exclusively to HPV6 and HPV11, whereas the approxi-
mately 10–17% of GW associated with other HPV types
observed in a number of different studies may be ex-
plained by FC and SWL [17-19].
In the WOLVES study population, the majority, but
not all, external GWs were confirmed as TCA. All five
cases with typical acuminate warts were associated with
HC2-LR-positive cervical samples and detection of HPV6
by SPF-10-PCR genotyping, while cervical samples of both
cases with SWL lesions tested negative for HC2-LR, al-
though HPV6 and HPV16 were detected in the wart tis-
sue. The number of GW classified colposcopically is still
too small for an assessment of our hypothesis of HPV
type-specific clinical pictures, but we hope that follow-up
data over 5 years from WOLVES and other studies will
provide definitive evidence.
The observed incidence of 715 GW per 100,000
women (9/1258) during the observation period corres-
ponds well with calculations based on healthcare provi-
ders’ studies and cross-sectional studies for urban regions
in Western Germany and shows that these approaches
may provide reliable data [1,20]. In the 1983/84 cohort,
3.9% (26/659) reported a history of GW compared with
0.7% in the 1988/89 cohort; the corresponding total life
risks for GW on 31 December 2010 were 4.8% (1983/84)
and 1.4% (1988/89). If the younger population (1988/89
cohort) continues with similar incidence rates over the
next 5 years, the cumulative rate of GW will be lower than
the corresponding rate observed in the 1983/84 cohort.
The most important explanation for this emerging pattern
may be that 126 women born 1988/89 (21%) had a full
course of quadrivalent HPV vaccination compared with
only 40 women (6%) in the older cohort. It has been
shown that HPV vaccination is highly efficient in preven-
ting GW and will result in a rapid decline of this disease
within a few years in populations with high vaccine cove-
rage [21,22]. After correction for this potential bias, by ex-
clusion of vaccinated participants in our study population,
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both cohorts are likely to show similar total life risks at
the same age in 2010 and 2015.
Although we found a significant burden of disease,
neither incidence nor life-time risk for GW reached the
high levels observed in four Nordic countries [23]. How-
ever, in Wolfsburg, as seen in other investigations, GW
were associated with a need for multiple treatments and
had an adverse impact on psychological, social and sexual
functions [24]. Our real-life findings agree with cross-
sectional investigations showing that the estimated costs
associated with the treatment of GW is substantial [20,25].
The results of the multivariate logistic regression showed
that only a higher number of sexual partners increased the
risk for LR-HPV type infection. Other risk factors such
as age at sexual debut or smoking were not significant.
Nevertheless, it is notable that eight of nine patients with
GW were current smokers. Although the numbers are too
small for statistical analysis, our observation is consistent
with a concept that risk factors for the acquisition of HPV
infection are different from those (co-factors) associated
with the development of clinically relevant disease. The
number of sexual partners and smoking have been identi-
fied as risk factors associated with HPV infection in other
recent studies, although these data related to overall preva-
lence of HPV rather than LR-HPV specifically [26,27].
LR-HPV types are purported to cause a substantial
proportion of low-grade and borderline findings on cy-
tology. We also found an increased rate of abnormal Pap
smears (8/107), but most cases were related to HR-HPV
types in women with multiple HPV-type infections.
Three out of five patients with TCA had abnormal Pap
smears and two of these abnormalities were linked to va-
ginal and/or cervical condylomata.
Conclusions
WOLVES is the first population-based trial that provides
real-life data on the epidemiology of LR-HPV in young
women in Germany. Our standardized approach to in-
vestigate the epidemiology of LR-HPV types in young
German women with the use of HC2 seems feasible. Ge-
notyping of an HC2-negative control group shows that a
small number of probably latent infections will be missed
by this concept, but HC2-LR accurately detected all LR-
HPV types, defined by Munoz et al., and related types
(e.g. HPV74) that were described in recent studies as
LR-HPV. We speculate that HC2-LR may be useful in
discriminating future LR from HR-HPV types. The ob-
served LR-HPV prevalence of 8.5% is in accordance with
results from similar studies in Italy and Spain [14,28].
HPV6 was the most common LR type found in the
WOLVES population, followed by HPV types 42, 11 and
44. In contrast, the prevalence of HPV6 was only 2.1%
and less than one-quarter of HC2-LR cases were related
to HPV6, while all cases of LR-HPV-associated diseases
were exclusively related to this type. Of 26 cases with
cervical HPV6 infections, five presented with TCA, one
with FC and three showed abnormal Pap smears. We ex-
pect to diagnose lesions related to other LR-HPV types
during future follow-up, but in accordance with other
investigations our findings underline the peculiar role of
HPV6 and question the clinical relevance of LR-HPV
infections other than HPV types 6 and 11.
Most established co-factors in the genesis of HR-HPV
infections and associated neoplasia and GW showed no
association with LR-HPV infections in the WOLVES
study population. The single co-factor associated with
a significantly increased risk for LR-HPV was a high
number of sexual partners. This may be different for the
development of GW, which were observed almost exclu-
sively in smokers, and further research is mandatory.
Similarly, our hypothesis of an HPV type-specific clinical
morphology of lesions needs to be confirmed in larger pa-
tient numbers. To date, all TCA were related to HPV6.
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